Home › Funds › Squadron Capital Management LLC › KTTA

Squadron Capital Management LLC position in KTTA

Pasithea Therapeutics Corp · Health Care

Squadron Capital Management LLC reported holding 1,000,000 shares of KTTA (Pasithea Therapeutics Corp) in its Q2 2026 13F filing — a position valued at US$515K, representing 0.20% of its reported portfolio and ranking #35 among its reported holdings. Squadron Capital Management LLC has disclosed KTTA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)1.00M sh
Reported value held$515.40K
Portfolio Weight0.20%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Squadron Capital Management LLC's KTTA position evolved

Squadron Capital Management LLC first disclosed a stake in KTTA in Q4 2025 at 2,100,000 shares (US$2.7M). Across 3 filings, Squadron Capital Management LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,000,000 shares valued at US$515K — a reduction of -1,100,000 shares quarter over quarter.. Notable position changes include a 52% trim in Q2 2026 (shares fell 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 2.10M $2.71M New
Q1 2026 2.10M $1.56M Hold
Q2 2026 1.00M $515.40K Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KTTA and 13F data

KTTA (Pasithea Therapeutics Corp) is a Health Care company. 26 other funds we track also report a position in KTTA — the largest reported positions include Stonepine Capital Management, LLC (US$1.1M), Vivo Capital, LLC (US$240K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KTTA

All KTTA fund holders →

FAQ

How long has Squadron Capital Management LLC held KTTA?

Squadron Capital Management LLC has disclosed KTTA holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Squadron Capital Management LLC's current position in KTTA?

As of Q2 2026, Squadron Capital Management LLC holds 1.00M shares of KTTA (Pasithea Therapeutics Corp), valued at $515.40K, representing 0.20% of its reported portfolio and ranking #35.

Has Squadron Capital Management LLC been buying or selling KTTA?

In the latest 13F filing (Q2 2026), Squadron Capital Management LLC reduced its position in KTTA.

Which other funds hold KTTA?

Other major institutional holders of KTTA include Stonepine Capital Management, LLC, Vivo Capital, LLC, among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.